Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Open accessThe DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lin, X., Wang, S., Sun, M., Zhang, C., Wei, C., Yang, C., Dou, R., Liu, Q., & Xiong, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0708-7 · Cited by 207
RetractedZhang, D., Qiu, X., Li, J., Zheng, S., Li, L., & Zhao, H. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1556064 · Cited by 72
RetractedBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Cited by
Items 101–200 of 436
Kennedy, B. M., & Harris, R. E. (2023) · Cancers · doi:10.3390/cancers15082380 · Cited by 15
“These included well-known receptor tyrosine kinase genes (EGFR, TEK and OSMR) that activate MAPK and PI3K signaling pathways [40], and other tumor-promoter genes (ATP8B2, DAAM1, SLAMF8 and SRGN) [50–53] as well as tumor-suppressor genes (A2M, DAPK1, RASSF8 and SOCS3) [54–57].”
BackgroundRole of imbalanced gut microbiota in promoting CRC metastasis: from theory to clinical application
Fan, S., Zhou, L., Zhang, W., Wang, D., & Tang, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01615-9 · Cited by 15
Műzes, G., & Sípos, F. (2025) · Cells · doi:10.3390/cells14100730 · Cited by 15
Shukla, S., Shukla, A. K., Upadhyay, A. M., Ray, N., Fahad, F. I., Nagappan, A., Dutta, S. D., & Mongre, R. K. (2025) · Onco · doi:10.3390/onco5020027 · Cited by 18
Wan, M., Mei, J., Cai, Y., Zhou, J., Xue, N., Jiang, Y., Zhang, Y., Huang, J., & Zhu, Y. (2025) · Advanced Science · doi:10.1002/advs.202501341 · Cited by 16
Cheng, C., Wang, Q., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610858 · Cited by 20
Huang, C., Yi, H., Zhou, Y., Zhang, Q. H., & Yao, X. (2022) · Cancers · doi:10.3390/cancers14153735 · Cited by 14
“The MAPK signaling pathway is related to the occurrence, progression, and metastasis of colorectal cancer [37,38].”
BackgroundFerreira, R. C., Duarte, S. S., de Sousa, V. M., de Souza, R. R. M., Marques, K. K. G., de Abrantes, R. A., do Nascimento, Y. M., de Sousa, N. F., Scotti, M. T., Scotti, L., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111553 · Cited by 13
“Therefore, stimulating the activity of these kinases can be involved in either a pro-tumoral or anti-tumoral effect [69,70].”
BackgroundSantarelli, R., Pompili, C., Montani, M. S. G., Evangelista, L., Gonnella, R., & Cirone, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030663 · Cited by 15
“Among the pro-inflammatory pathways activated in IBD and playing a key role in the control of cytokine release, there are ERK1/2 and PI3K/AKT/mTOR.”
BackgroundInfluentialTang, D., Huang, Y., Che, Y., Yang, C., Pu, B., Liu, S., & Li, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323418 · Cited by 12
Di, J., Wei, B., Wang, C., & Liu, C. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673315460240816091032 · Cited by 13
Tao, Y., Li, J., Pan, J., Wang, Q., Ke, R., Yuan, D., Wu, H., Cao, Y., & Zhao, L. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s499806 · Cited by 13
“33 Additionally, ATP13A2 activates the pentose phosphate pathway and promotes CRC growth through the TFEB-PGD axis.”
Khamis, T., Diab, A. E.-A. A., Zahra, M. H., Eldahmy, S., Al-Hameed, B. A. A., Abdelkhalek, A., Said, M. A., Abdellatif, H., Fericean, L. M., Bănățean-Dunea, I., et al. (2023) · Molecules · doi:10.3390/molecules28145543 · Cited by 12
“These alterations lead to the dysregulation of several signaling pathways, including the Wnt/β-catenin, PI3K/Akt/mTOR, and MAPK/ERK pathways, among others [88].”
BackgroundGuendouzi, A., Belkhırı, L., Djelti, F., Zendaoui, Z. M., Brahim, H., Guendouzi, A., Djekoun, A., & Boucekkine, A. (2024) · Molecular Simulation · doi:10.1080/08927022.2024.2326180 · Cited by 12
“Similarly, the inhibition of uncontrolled mitogen-activated protein kinase (MAPK) signalling pathway as well as PI3K-AKT (mTOR) downstream pathway, is related to di ff erent type of cancer therapy [67].”
BackgroundFXR1 promotes proliferation, invasion and migration of hepatocellular carcinoma in vitro and in vivo
Zhao, K., Gao, J., Shi, J., Shi, C., Pang, C., Li, J., Guo, W., & Zhang, S. (2022) · Oncology Letters · doi:10.3892/ol.2022.13608 · Cited by 12
Li, M., Zhou, H., Pan, Z., Shi, M., Yang, J., Guo, J., & Wan, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107416 · Cited by 11
Sultan, M. H., Zhang, Q., Wang, Y., Xia, Y., & Jia, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5545 · Cited by 11
“Synergy between OVT and ICIs.”
Dalamaga, Μ., Rozani, S., & Petropoulou, D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00700-z · Cited by 12
“Obesity and T2DM further exacerbate systemic and local inflammation through altered adipokine secretion, macrophage polarization, and impaired intestinal barrier function [ 39, 40 ].”
The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
Voutsadakis, I. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175132 · Cited by 12
“Through down-stream activation of the mTORC1 complex, AKT positively regulates protein translation and cell growth [10,11].”
BackgroundSong, L., Jiang, Z., Zhang, X., Song, Y., Xing, Y., & Wang, G. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03595-2 · Cited by 11
“The MAPK pathway is related to the AKT pathway [28].”
BackgroundXu, X., Deng, L., Tang, Y.-L., Li, J., Zhong, T., Hao, X., Fan, Y., & Mu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098113 · Cited by 11
Lee, J., & Kim, S. Y. (2023) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2023.083 · Cited by 11
Zhou, B., Guo, Y., Zhao, M., Li, Y., Li, J., Xiang, Y., Tong, L., Chu, X., Wang, C., & Song, Y. (2023) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-023-02995-6 · Cited by 12
“* P 0.05 the two signaling pathways are crucial for normal development and pathological disorder [29, 40].”
InfluentialYalamarty, R., Magesh, S., John, D., Chakladar, J., Li, W. T., Brumund, K. T., Wang‐Rodriguez, J., & Ongkeko, W. M. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101100 · Cited by 12
Yang, K., Zhang, T., Niu, R., Zhao, L., Cheng, Z., Li, J., & Wang, L. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1483574 · Cited by 11
“…and metabolic balance, and its dysregulation is linked to diseases such as cancer, diabetes, and growth disorders (Mancarella et al., 2021; Forbes et al., 2020; Altieri et al., 2019; Okuyama et al., 2021; Stefani et al., 2021; Jiating et al., 2019; Yang et al., 2020; Chaumont-Dubel et al., 2020).”
BackgroundSanie‐Jahromi, F., Arman, A., Attar, A., & Nowroozzadeh, M. H. (2024) · Contact Lens and Anterior Eye · doi:10.1016/j.clae.2024.102343 · Cited by 10
Oliveira, S. B., Machado, M., Sousa, D., Pereira, S. S., & Pignatelli, D. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09945-w · Cited by 10
“…known to be part of a complex—IGF2 system—which activates signaling pathways, such as mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) pathways, involved in proliferation, survival, and cell metastasis [23, 46–48].”
ID3 enhances PD-L1 expression by restructuring MYC to promote colorectal cancer immune evasion
Huang, C., Wang, L., Zhuo, C., Chen, W., Fan, H., Hong, Y., Zhang, Y., Zhou, D., Lin, W., Zhang, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423490122 · Cited by 11
“The Ras and MAPK signaling pathways are critical in the eukaryotic signal transmission network and play a role in the regulation of various cell behaviors related to cancer development, including proliferation, differentiation, apoptosis, inflammation, and immunity ( 52 ).”
Targeting the MAP Kinase Pathway in Colorectal Cancer: A Journey in Personalized Medicine
Appleyard, J. W., Williams, C. J. M., Manca, P., Pietrantonio, F., & Seligmann, J. F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0107 · Cited by 11
Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives
Zhang, R., Tan, Y., Jiang, D., Kong, D., Liu, M., Liang, J., Wu, A., & Wang, L. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189401 · Cited by 12
Zheng, T., Yu, X., Yu, C., Xu, W., Fan, Z., Zhou, Y., Li, C., Wan, J., Jin, C., Jin, X., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00883-y · Cited by 11
Kusumaningrum, A. E., Makaba, S., Ali, E., Singh, M., Fenjan, M. N., Rasulova, I., Misra, N., Al‐Musawi, S. G., & Alsalamy, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3906 · Cited by 11
“79,80 Unlike VEGFR ‐ 1, VEGFR ‐ 2 actively promotes the formation of new blood vessels.”
BackgroundDual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer
Liu, X., Xu, W., Li, L., Zhang, Z., Lü, M., & Xia, X. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.84320 · Cited by 10
“SHP-2 feedback activates the downstream PI3K/mTOR and MAPK pathway [9,10,11] .”
BackgroundLiu, S., Zhou, Y., Chen, Y., Qiao, Y., Bai, L., Zhang, S., Men, D., Zhang, H., Pan, F., Gao, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112828 · Cited by 10
Role of ERK1/2 and p38 Protein Kinases in Tumors: Biological Insights and Clinical Implications
Emelyanova, A., Modestov, A., Buzdin, A. A., & Poddubskaya, E. V. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl31317 · Cited by 12
Li, S., Zhu, X., Qin, B.-C., & Chen, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1667731 · Cited by 14
Wang, C., He, Y., He, Y., Liang, W., Zhou, C., Wu, M., Meng, Z., Li, W., & Cao, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02824-1 · Cited by 10
Li, F., Wang, L., Wang, Y., Shen, H., Kou, Q., Shen, C., Xu, X., Zhang, Y., & Zhang, J. (2023) · Journal of Cancer · doi:10.7150/jca.87545 · Cited by 9
“The aberrant activation of AKT/mTOR signaling pathway is considered to be a classical oncogenic factor of CRC [17, 18].”
BackgroundTang, R., Zhang, Z.-F., Xu, J., Wang, W. J., Meng, Q., Liu, Y., Du, Q., Liang, C., Hua, J., Zhang, B., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.021 · Cited by 10
“For fibroblasts, their secreted exosome-miRNAs may regulate genes involved in MAPK signaling and PI3K-Akt signaling, which have been widely reported as oncogenic pathways in cancer [33,35,46] (Fig.”
Wen, S., Xiao, H., Yang, P., Zhang, Y., Bu, F., Wu, Y., Sun, Q., Wang, G., & Ouyang, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02392 · Cited by 10
Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights
Srivastava, S., Anand, A. K., Kandhula, A. G., Jaiswal, P., Kumar, S., Gulati, M., Sachdeva, M., & Behl, T. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096338273241224061021 · Cited by 14
Colorectal cancer-derived exosomes and modulation KRAS signaling
Wan, Y. H., Liu, Q. S., Wan, S. S., & Wang, R. W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02877-w · Cited by 11
“Using preclinical models, the combination of RAF-MEK-ERK and PI3K-AKT-mTOR suppression has shown improved anticancer efficacy [62, 63].”
BackgroundYazdi, S. A. M., Bakhshi, N., Nazar, E., Tabriz, H. M., & Gorji, R. (2022) · International Journal of Surgery Open · doi:10.1016/j.ijso.2022.100527 · Cited by 9
Association of Neurokinin-1 Receptor Signaling Pathways with Cancer
Rodriguez, F. D., & Coveñas, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230818110812 · Cited by 10
Elwan, A. H., El-Masry, S. M., Habib, D. A., & Zewail, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106292 · Cited by 9
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
“This results in the sustained activation of kinases, such as Akt and MAPK, driving tumor growth in melanoma, GBM, and CRC [114, 278–280].”
An, Y., Song, H., Qiu, H., Jiang, J., & Shi, J. (2025) · Cancer Medicine · doi:10.1002/cam4.70975 · Cited by 9
“Phosphatidylinositol-3,4,5-trisphosphate (PIP3): The PI3K/ Akt/mTOR signaling pathway plays a central role in cancer cell growth, survival, and metabolism [102, 103, 119, 120].”
Adipose Tissue Engineering Biomaterials: Smart Scaffolds, Vascularization, and Clinical Frontiers
Zhao, X.-Y., Li, P.-C., Chen, Y.-M., Cao, K., Wei, W. E. I., Aziz, Y., & Zrínyi, M. (2026) · Biomolecules · doi:10.3390/biom16030362 · Cited by 8
Zheng, Q., Wang, X., Gao, T., Zhang, B., Zhao, N., Du, R., & Zhao, Z. (2023) · Medicine · doi:10.1097/md.0000000000036602 · Cited by 8
“[45] For example, Cheng et al provided detailed insights into the inhibitory effects of naringin on CRC cell lines, elucidating that hesperidin, in a dose-dependent manner, arrests cell proliferation and induces apoptosis by suppressing the PI3K/ AKT/mTOR signaling pathway.”
BackgroundEpigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer
Bao‐Caamano, A., Costa‐Fraga, N., Cayrefourcq, L., Rodríguez‐Casanova, A., Muinelo‐Romay, L., López‐López, R., Alix‐Panabières, C., & Díaz‐Lagares, Á. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1291179 · Cited by 8
Vinothkanna, A., Shi‐Liang, X., Rajan, D. K., Prathiviraj, R., Sekar, S., Zhang, S., Wang, B., Liu, Z., & Jia, A. (2024) · Food Frontiers · doi:10.1002/fft2.406 · Cited by 8
New insights into the role of complement system in colorectal cancer (Review)
Xu, Y., Zhou, J., Wu, Y., Shen, J., Fu, X., Liu, M., & Liang, S. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13433 · Cited by 8
YektaKooshali, M. H., SobhZahedi, M., Tousi, S. M. T. R., Hamidi, M., & Modiri, L. (2025) · BMC Cancer · doi:10.1186/s12885-024-13401-4 · Cited by 9
“The PI3K signaling pathway transmits signals from growth factors and other extracellular stimuli to the cell, leading to the activation of mTOR (mechanistic target of rapamycin) and subsequent control of cell growth and metabolism [27].”
Therapeutic Potential of Prunus Species in Gastrointestinal Oncology
Mitea, G., Iancu, I. M., Schröder, V., Roșca, A. C., Iancu, V., Crețu, R., & Mireşan, H. (2025) · Cancers · doi:10.3390/cancers17060938 · Cited by 8
“…and downstream molecules ( KRAS and NRAS : RAS family genes; Ras: small G-protein; BRAF : B-Raf proto-oncogene serine/threonine kinase; ERBB2 and ERBB3: ERBB epidermal growth factor receptor) [79,85,86] play a role in regulating cell motility in both gastric cancer (GC) and normal epithelial cells.”
Investigating the PI3K/AKT/mTOR axis in Buzhong Yiqi Decoction’s anti-colorectal cancer activity
Qiao, S., Li, X., Yang, S., Hua, H., Mao, C., & Lu, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-89018-9 · Cited by 11
“PI3K is triggered by growth factor receptor signaling, serving as a second messenger that mediates signals to various cellular targets 31 .”
Zamanian, M. Y., Darmadi, D., Darabi, R., Al-Aouadi, R. F. A., Ivraghi, M. S., & Akkol, E. K. (2025) · Bioimpacts · doi:10.34172/bi.31211 · Cited by 8
“63 However, most PI3K inhibitors have demonstrated toxic or undesirable side effects during in vitro testing.”
Guo, J., Yuan, Q., Fang, Y., Liao, J., & Zhang, Z. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0498 · Cited by 8
“In VEGF-induced tumor cells, the PI3K/AKT/mTOR pathway, which is the downstream pathway of VEGFR, can be activated to mediate the adhesion, proliferation, and migration of endothelial cells [42].”
BackgroundMelatonin improves the vitrification of sheep morulae by modulating transcriptome
Ji, P., Liu, Y., Yan, L., Jia, Y., Zhao, M., Lv, D., Yao, Y., Ma, W., Yin, D., Liu, F., et al. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1212047 · Cited by 9
Shao, Y., Chen, J., Hu, Y., Wu, Y., Zeng, H., Lin, S., Lai, Q., Fan, X., Zhou, X., Zheng, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1000639 · Cited by 8
“To meet the demands of the TME, metabolic reprogramming occurs throughout the tumorigenesis, including lipid metabolism (Ma and Zhang, 2021), glucose metabolism (Lyssiotis and Kimmelman, 2017), ion metabolism (Andersen et al., 2014), etc. Targeting metabolism in tumors has recently been regarded as a novel therapeutic…”
BackgroundInfluentialBiophysical cues involved in the stem cell niche for stemness maintenance
Li, C., Zheng, L., & Fan, Y. (2024) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2024.100301 · Cited by 7
Chen, L., Li, X., Zhao, S., Hao, M., Wang, H., Zhou, Z., Xiong, X., Yuan, D., Luo, P., Wang, L., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091378 · Cited by 8
Fan, X., Shi, J., Shang, Y., & Xu, H. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1795133 · Cited by 8
“…liquid biopsy CRC initiation and progression involve coordinated dysregulation across multiple layers—including genomic alterations, epigenetic regulation, transcriptional reprogramming, protein expression, and metabolic remodeling, forming a complex network (Stefani et al., 2021; Li et al., 2024).”
Park, S. J., Shin, K., Hong, T. H., Lee, S. H., Kim, I.-H., Kim, Y.-H., & Lee, M. A. (2024) · Cancers · doi:10.3390/cancers16152756 · Cited by 7
“This EGFR-mediated activation triggers oncogenic signaling cascades, including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, which promote tumor growth and progression [10].”
BackgroundWang, C.-L., Yang, B.-W., Wang, X., Xue, C., Li, W., Zhai, H.-Y., Wu, Y., Cui, M.-Y., Wu, J., Meng, Q., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i8.3539 · Cited by 7
Lim, H.-I., Kim, G. Y., Choi, Y., Lee, K., & Ko, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02056-7 · Cited by 8
“AKT1 is frequently activated in CRC, and its activation has been associated with the development and progression of the disease (Activated AKT1 promotes cell survival and proliferation by regulating downstream targets involved in cell cycle regulation, apoptosis, and metabolism [63].”
NMB promotes the progression of colorectal cancer by regulating the NF-κB/P65 signaling pathway
Fan, J., Liu, Y., Wang, J., Tian, Y., Bai, S., Ma, X., Chen, H., Chen, Y., Gao, H., Guo, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1596451 · Cited by 8
Regulation of Matrix Metalloproteinases by Wine-Derived Compounds: Implications for Cancer Therapy
Islam, M. T., Vo, H. V. T., & Lee, H. J. (2025) · Biomolecules · doi:10.3390/biom15060781 · Cited by 7
Kumbrink, J., Li, P., Pók-Udvari, Á., Klauschen, F., Kirchner, T., & Jung, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212364 · Cited by 7
“These and other studies showed that Wnt/β-catenin, KRAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase/AKT serine-threonine protein kinase (PI3K/AKT) signaling pathways are commonly deregulated in CRC [10,11].”
BackgroundHuang, L., Sha, Y., Liang, W., Mo, C., Li, C., Deng, Y., Gong, W., Hou, X., & Ou, M. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01619-3 · Cited by 7
“There have been reports that MAPK, Wnt, and P53 signaling pathway are typical cancer-related pathways that are closely associated with cancer development, metastasis and invasion [19–23].”
BackgroundWang, Y., Yan, R., Ye, L.-R., Tang, C., Zhou, H., & Zhao, G. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s505423 · Cited by 6
“31 Therefore, it was suggested that GQD ameliorates colitis through inhibiting the overexpression of inflammatory cytokines.”
Investigation of novel nimesulide derivatives against breast cancer
Birgül, K., Atlıhan, İ., Dere, D., Yelekçi, K., Tiber, P. M., Orun, O., & Küçükgüzel, Ş. G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108850 · Cited by 6
Moreau, G. B., Tian, J., Natale, N. R., Naz, F., Young, M. K., Nayak, U., Tanyüksel, M., Rigo, I., Madden, G. R., Abhyankar, M. M., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.195678 · Cited by 6
Hasan, R., Shaikh, M. T. M., Rawat, S., Singh, V., Tamang, R., & Choudhury, S. (2026) · Scientific Reports · doi:10.1038/s41598-025-31383-6 · Cited by 6
“Activation of one of the major pathway was MAPK signaling pathway , suggests microbial contribution to inflammation and tumorigenesis via cell proliferation 60 .”
Diaz, F. C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2026) · Cancers · doi:10.3390/cancers18020293 · Cited by 6
“A central axis in CRC pathobiology is the EGFR-RAS-RAF-MEK-ERK (MAPK) signaling cascade, which regulates proliferation, survival, invasion, and therapy resistance [5,6].”
Yang, L., Akbarabadi, P., & Babashah, S. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189545 · Cited by 6
Manshi, Dash, D., & Koiri, R. K. (2026) · Endocrine · doi:10.1007/s12020-026-04561-3 · Cited by 7
Mohamed, S. S., Ahmad, A., Mutalib, N. A., Din, T. A. D. A. T., Salleh, M. S. M., Zakaria, A. D., & Zakarıa, Z. (2023) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000343 · Cited by 8
Qin, Y., Yang, Y., Ren, Y.-H., Gao, F., Wang, M., Li, G., Liu, Y., & Fan, L. (2023) · Medicine · doi:10.1097/md.0000000000035829 · Cited by 7
“[40] In conclusion, these findings suggest that MAPK family genes, especially ERK, JNK, and P -38 MAPK, can serve as prognostic markers for pan-cancer.”
BackgroundPadarath, K., Deroubaix, A., Naicker, P., Stoychev, S., & Kramvis, A. (2024) · Viruses · doi:10.3390/v16071052 · Cited by 6
“These pathways regulate cell growth, motility, survival, and metabolism [83–86] (Figure 10).”
BackgroundLi, R., Wu, H., Ran, F., He, Y., Sun, H., Peng, W., Wang, Q., & Li, J. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.07.006 · Cited by 8
Hamouda, S. B., Zakraoui, O., Souissi, S., Bouzeyen, R., Essafi, M., & Essafi‐Benkhadir, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188876 · Cited by 6
“Due to the critical role of the MAPK and AKT signaling pathways in regulating cellular growth and survival in colorectal cancer [21,33,34], targeting their components is considered a valuable approach in the anticancer therapy.”
Osotprasit, S., Suwansa‐ard, S., Cummins, S. F., Wang, T., Samrit, T., Chaiwichien, A., Smith, S. J., Changklungmoa, N., & Kueakhai, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110514 · Cited by 6
“The downregulation of MAPK3 may reflect inhibition of signaling through the ERK cascade, while the upregulation of CBL, an E3 ubiquitin ligase that regulates EGFR degradation, may be a mechanism to reduce excessive EGFR activation [56,57].”
Wang, S., Ding, Q., Xiu, A., Xia, Y., Wang, G., & Zhang, C. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18047 · Cited by 7
Theranostic applications of peptide-based nanoformulations for growth factor defective cancers
Ghosh, A., Maske, P., Patel, V., Dubey, J., Aniket, K., & Srivastava, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.129151 · Cited by 6
Pathways and molecules for overcoming immunotolerance in metastatic gastrointestinal tumors
Gan, Q., Li, Y., Li, Y., Liu, H., Chen, D., Liu, L., & Peng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359914 · Cited by 6
Acharya, R., Kumari, S., Shetty, S. S., Shetty, A. S., Monteiro, F., & Roopashree, P. G. (2024) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_125_24 · Cited by 6
Natural Stilbenes: Their Role in Colorectal Cancer Prevention, DNA Methylation, and Therapy
Fialková, V., Ďúranová, H., Borotová, P., Klongová, L., Grabacka, M., & Speváková, I. (2024) · Nutrition and Cancer · doi:10.1080/01635581.2024.2364391 · Cited by 6
“…the tumor micro-environment play a key role in CRC development through the activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and other major sub-families of the mitogen-activated protein kinase (MAPK) signaling pathways (62,63).”
Early-life antibiotic exposures: Paving the pathway for dysbiosis-induced disorders
Attiq, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177298 · Cited by 7
Analysing DNA methylation and transcriptomic signatures to predict prostate cancer recurrence risk
Aldakheel, F. M., Alnajran, H., Alduraywish, S. A., Mateen, A., Alqahtani, M. S., & Syed, R. (2025) · Discover Oncology · doi:10.1007/s12672-025-01833-8 · Cited by 6
Li, X., Chen, Y., Li, X., Yang, X., Zhou, L., Cheng, Y., Hou, H., Yang, D., Gong, Y., Xiao, H., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01635-9 · Cited by 8
“In HCT-116 colon cancer cells, leptin can induce cancer by activating the PI3K-AKT signaling pathway [53].”
Prognostic gene expression profile of colorectal cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Baldaniya, L., Ballal, S., Vashishth, R., Parmar, M., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149433 · Cited by 6
Zhou, L., Liu, Y., Zhai, F., Liu, B., Liu, D., & Yi, B. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106937 · Cited by 6
Abdrabou, A., Shalby, A. B., & Kotob, S. E. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01132-5 · Cited by 6
“Further, the WHO has reported that CRC remains one of the leading causes of cancer-related deaths globally [13].”
BackgroundHigh Expression of circ_0001821 Promoted Colorectal Cancer Progression Through miR-600/ISOC1 Axis
Li, C., Gao, X., Zhao, Y. D., & Chen, X. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10262-z · Cited by 6
“The disease is also affected by lifestyle habits, diet, living environment, and genetic factors (Jung et al. 2021; Stefani et al. 2021).”
BackgroundInteraction of lncRNAs with mTOR in colorectal cancer: a systematic review
Moslehian, M. S., Shabkhizan, R., Asadi, M. R., Bazmani, A., Mahdipour, M., Haiaty, S., Rahbarghazi, R., & Sakhinia, E. (2023) · BMC Cancer · doi:10.1186/s12885-023-11008-9 · Cited by 8
Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2
Wang, M., Yang, S., Li, X., Zheng, Y., Bai, Y., Luo, W., Zhu, G., Chang, J., & Zhu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01434 · Cited by 5
Ayoup, M. S., Ghanem, M., Abdel‐Hamid, H., Elghamry, I., Abu-Serie, M. M., Masoud, A. A., Ghareeb, D. A., Harras, M. F., Ismail, M. M. F., & Negm, A. (2025) · Polycyclic aromatic compounds · doi:10.1080/10406638.2025.2476071 · Cited by 6
Yavaş, A., & Akan, E. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70476 · Cited by 5
“…to activate the PI3K/AKT pathway downstream of their respective receptors, linking growth factor signaling to key cellular functions relevant to UC, such as epithelial repair (via EGF/EGFR/PI3K/AKT) and angiogenesis/inflammation (via VEGF/VEGFR/PI3K/AKT) (Chen et al. 2022; Stefani et al. 2021).”
Wu, Y., Liu, Q., Xiang, W., & Fu, P. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189410 · Cited by 6
Gheibi, M., Sadeghi, S., Hessami, A., Erfani, Z., Ghadirzadeh, E., & Moosazadeh, M. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.10.003 · Cited by 7
Metadata
- Authors
- Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M.
- Affiliations
- Department of Family Medicine and Clinical Base, ‘‘Dr. Carol Davila’ Central Military Emergency University Hospital, 051075 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania
- Spitalul Universitar de Urgenţă Militar Central Dr. Carol Davila (RO)
- Corresponding author
- Miricescu, Daniela
- Greabu, Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-23
- Volume
- 22
- Issue
- 19
- Pages
- 10260
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508474
- OpenAlex
- W3200117713
- Cited by
- 402
- References
- 206
- Citations by year
- 2026: 69 · 2025: 134 · 2024: 103 · 2023: 68 · 2022: 26 · 2021: 2
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, growth factors, PI3K/AKT/mTOR pathway, MAPK signaling, tumor microenvironment, EGFR, IGF-1 receptor, VEGF-A, growth factor inhibitors, colorectal cancer risk factors, colorectal cancer pathogenesis, cell proliferation and invasion
- MeSH terms
- Animals, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Intercellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

